What is Predicine?
Predicine is a biotechnology firm dedicated to advancing precision cancer therapies. Leveraging a next-generation liquid biopsy platform, the company provides critical molecular insights derived from non-invasive samples such as blood and urine. This capability facilitates early cancer detection and ongoing monitoring. Predicine's offerings encompass comprehensive molecular profiling assays and specialized solutions for biopharmaceutical clinical research, with a strategic focus on supporting biomarker-driven clinical trials. Their collaborations with leading biopharma entities aim to accelerate oncology drug development and enhance patient outcomes.
How much funding has Predicine raised?
Predicine has raised a total of $1.1M across 2 funding rounds:
Debt
$350K
Debt
$703K
Debt (2020): $350K with participation from PPP
Debt (2021): $703K led by PPP
Key Investors in Predicine
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Predicine?
The substantial enterprise-level investment signifies Predicine's maturation and its strategic importance within the precision medicine landscape. This capital infusion is expected to fuel further development of its liquid biopsy technology, expand its research collaborations, and potentially scale its commercial operations. The company is well-positioned to capitalize on the growing demand for non-invasive diagnostic tools in oncology, aiming to solidify its role in biomarker discovery and companion diagnostics for targeted therapies. Future growth will likely involve deepening partnerships with pharmaceutical companies and potentially exploring new therapeutic areas.
See full Predicine company page
